Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
Immunomedics, Inc.
G C C C A C A A A A A A A C C C C A C C A A A A C C C C C C C C A A C C C C A C C A C
G01N C07K C07K C07H A61K C07K A61K A61P A61K A61K A61K A61K A61K C07K C07K C07K C07K A61K C07K C07K A61K A61K A61K A61K C07K C07K C12N C07K C07K C07K C07K C07K A61K A61K C07K C07K C07K C07K A61K C07K C07K A61K C07K
inventional additional additional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional additional inventional additional additional inventional additional additional inventional inventional inventional inventional additional inventional inventional additional additional inventional additional additional inventional inventional inventional additional additional additional inventional additional additional inventional inventional
David M. Michele J. Chien-Hsing
Goldenberg Losman Chang